• Markets
    • icon
  • Companies
ZLD · ASX

Zelira Therapeutics Ltd. (ASX:ZLD)

AU$0.94

 0.0 (0.0%)
ASX:Live
01/12/2023 03:02:24 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ZLD Overview

ZLD Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About ZLD

Website

Zelira Therapeutics Ltd.

Telephone

61.8.6558.0886

Address

Level 3 101 St George’s Terrace Perth, Western Australia (WA) 6000

Description

Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The firm engages in the research and development of cannabinoid-based formulations for the treatment of a variety of medical conditions. It focuses on human clinical trial program and pre-clinical research program. The company was founded by Harry Karelis, Mara Gordon, Jason Peterson, and Stewart Washer on February 18, 2003 and is headquartered in Perth, Australia.

ZLD Price Chart

Key Stats

Market Cap

AU$11.69M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.9 - 3.35

Trade Value (12mth)

AU$7,823.00

1 week

-7.84%

1 month

-1.05%

YTD

-6%

1 year

-11.32%

All time high

20453.1

Key Fundamentals

EPS 3 yr Growth

-61.800%

EBITDA Margin

%

Operating Cashflow

-$7m

Free Cash Flow Return

-21.40%

ROIC

-16.50%

Interest Coverage

-89.60

Quick Ratio

0.10

Other Data

Shares on Issue (Fully Dilluted)

11m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ZLD Announcements

Latest Announcements

Date Announcements

31 October 23

September 2023 Quarterly Activities Report

×

September 2023 Quarterly Activities Report

31 October 23

Appendix 4C Cash Flow Report

×

Appendix 4C Cash Flow Report

31 October 22

September 2022 Quarterly Activities Report

×

September 2022 Quarterly Activities Report

31 October 22

Appendix 4C Cash Flow Report

×

Appendix 4C Cash Flow Report

31 October 06

Gleneagle Gold Limited - Annual Report

×

Gleneagle Gold Limited - Annual Report

31 May 23

Zeliras diabetic nerve pain drug outperforms Lyrica

×

Zeliras diabetic nerve pain drug outperforms Lyrica

31 May 23

Investor Webinar - Top line trial results

×

Investor Webinar - Top line trial results

31 May 23

Top Line Results Investor Presentation

×

Top Line Results Investor Presentation

31 May 23

Zelira Non-Executive Director Appointed

×

Zelira Non-Executive Director Appointed

31 May 23

Proposed issue of securities - ZLD

×

Proposed issue of securities - ZLD

31 July 23

June 2023 Quarterly Activities Report

×

June 2023 Quarterly Activities Report

31 July 23

Appendix 4C Cash Flow Report

×

Appendix 4C Cash Flow Report

31 January 23

December 2022 Quarterly Activities Report

×

December 2022 Quarterly Activities Report

31 January 23

Appendix 4C Cash Flow Report

×

Appendix 4C Cash Flow Report

31 January 22

December 2021 Quarterly Activities Report

×

December 2021 Quarterly Activities Report

31 January 22

Appendix 4C Cash Flow Report

×

Appendix 4C Cash Flow Report

31 January 22

Board Changes

×

Board Changes

31 January 22

Initial Director's Interest Notice

×

Initial Director's Interest Notice

31 January 22

Final Director's Interest Notice

×

Final Director's Interest Notice

31 August 23

Preliminary Final Report

×

Preliminary Final Report

31 August 22

Appendix 4E and Financial Report to Shareholders

×

Appendix 4E and Financial Report to Shareholders

31 August 22

Appendix 4G

×

Appendix 4G

31 August 22

Zelira Full Year Results

×

Zelira Full Year Results

30 September 22

Notification of cessation of securities - ZLD

×

Notification of cessation of securities - ZLD

30 September 21

Annual Report to shareholders

×

Annual Report to shareholders

30 September 10

Annual Report (GLN-AU)

×

Annual Report (GLN-AU)

30 November 18

Annual General Meeting Presentation 2018

×

Annual General Meeting Presentation 2018

30 May 22

ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial

×

ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial

ZLD Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -1.29 -1.54 -0.55 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -1.29 -1.54 -0.55 Lock Lock Lock
     Growth % Lock Lock Lock Lock 11.0 -19.8 64.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -1.18 -0.91 -0.71 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -1.30 -1.17 -0.72 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.8 23.0 21.7 Lock Lock Lock
     Yield % Lock Lock Lock Lock -17.3 -120.8 -47.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 5.56 3.68 2.80 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.88 0.36 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 91.9 -58.4 -94.1 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 7 8 10 Lock Lock Lock
Basic m Lock Lock Lock Lock 7 8 10 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 1 2 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 132.3 -80.5 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 10 8 4 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 -6 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 85.8 -14,496.2 43.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5.9 -371.0 -1,068.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 106 471 1,168 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -9 -13 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21.3 -39.8 46.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,383.6 -832.5 -2,280.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -10 -13 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.1 -39.0 44.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,455.1 -870.7 -2,461.7 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -10 -14 -7 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -9 -12 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21.9 -39.7 53.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,288.8 -775.4 -1,850.8 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -9 -9 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 1 0 3 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 11 7 2 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -9 -9 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.9 -9.4 23.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -13.0 -6.1 -24.1 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 5 3 0 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 39 38 34 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -4 -2 0 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 38 35 32 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 38 36 32 Lock Lock Lock
     Growth % Lock Lock Lock Lock 9.0 -7.1 -9.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -21.7 -31.7 -16.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.6 -33.9 -17.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -26.2 -36.0 -21.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -23.3 -32.3 -16.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -23.5 -25.5 -21.4 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -215.3 -238.2 -89.6 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.5 0.2 -0.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -11.7 -6.4 0.9 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.7 3.1 0.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 4.9 1.9 0.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 81.6 54.1 8.3 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -801.2 -579.5 -384.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 11.0 9.8 2.4 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 1.6 5.1 2.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.4 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 148.5 98.0 578.2 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -1,496.6 -889.6 -2,461.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -25.2 -36.4 -21.9 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -21.7 -31.7 -16.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.6 -33.9 -17.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -22.6 -33.9 -17.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 225.4 71.0 180.8 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 33.1 37.2 154.8 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 258.5 108.2 335.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 179.5 54.6 192.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 79.0 53.7 143.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ZLD Shortsell

Frequently Asked Questions

The current share price of Zelira Therapeutics Ltd. (ZLD:ASX) is AU$0.94.
The 52-week high share price for Zelira Therapeutics Ltd. (ZLD:ASX) is AU$3.35.
The 52-week low share price for Zelira Therapeutics Ltd. (ZLD:ASX)? is AU$0.90.
Zelira Therapeutics Ltd. (ZLD:ASX) does not pay a dividend.
Zelira Therapeutics Ltd. (ZLD:ASX) does not pay a dividend.
Zelira Therapeutics Ltd. (ZLD:ASX) does not offer franking credits.
Zelira Therapeutics Ltd. (ZLD:ASX) is classified in the Healthcare.
The current P/E ratio for Zelira Therapeutics Ltd. (ZLD:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.